Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma

Mary Kate Malecek, Marcus P. Watkins, Nancy L. Bartlett

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Introduction: Polatuzumab vedotin is an antibody–drug conjugate comprised of an anti-CD79b monoclonal antibody conjugated to monomethyl auristatin (MMAE), a microtubule-disrupting cytotoxin. CD79b is almost exclusively expressed on normal and malignant B-cells, making it an appealing target for novel therapeutics. Areas covered: This article reviews the current literature on polatuzumab vedotin, including its pharmacology, as well as summarizing the results of clinical trials in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as a single agent and in combination with other chemotherapies and chemoimmunotherapies. The current landscape of approved therapies for relapsed and refractory DLBCL, as well as other promising novel approaches, is discussed. Expert opinion: The recent approval of polatuzumab vedotin in combination with bendamustine and rituximab (BR) offers another option to patients with DLBCL who are not eligible for autologous hematopoietic cell transplant or chimeric antigen receptors (CAR)-T cell therapy. In younger patients and those without serious comorbidities, polatuzumab vedotin-BR may serve as bridging therapy to more intensive therapies with reasonable efficacy and tolerability. Polatuzumab vedotin is currently being studied in a randomized trial in the front line setting in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

Original languageEnglish
Pages (from-to)831-839
Number of pages9
JournalExpert opinion on biological therapy
Issue number7
StatePublished - 2021


  • CD79b
  • Diffuse large B cell lymphoma
  • antibody-drug conjugate
  • polatuzumab vedotin


Dive into the research topics of 'Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this